MBRX · Moleculin Biotech, Inc.
AI read · Good for MBRX
The AI's read
This brings Moleculin closer to choosing a dose for the next trial stage. A published review found no heart damage tied to Annamycin across five trials. But the full Part A results are still pending, so its benefit for AML patients has not yet been shown.